325 related articles for article (PubMed ID: 22759794)
1. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology.
Gotter AL; Webber AL; Coleman PJ; Renger JJ; Winrow CJ
Pharmacol Rev; 2012 Jul; 64(3):389-420. PubMed ID: 22759794
[TBL] [Abstract][Full Text] [Related]
2. Orexin receptor antagonists: a review of promising compounds patented since 2006.
Coleman PJ; Renger JJ
Expert Opin Ther Pat; 2010 Mar; 20(3):307-24. PubMed ID: 20180618
[TBL] [Abstract][Full Text] [Related]
3. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
[TBL] [Abstract][Full Text] [Related]
4. Orexin neuronal circuitry: role in the regulation of sleep and wakefulness.
Ohno K; Sakurai T
Front Neuroendocrinol; 2008 Jan; 29(1):70-87. PubMed ID: 17910982
[TBL] [Abstract][Full Text] [Related]
5. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
6. Orexin receptors: pharmacology and therapeutic opportunities.
Scammell TE; Winrow CJ
Annu Rev Pharmacol Toxicol; 2011; 51():243-66. PubMed ID: 21034217
[TBL] [Abstract][Full Text] [Related]
7. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
Roecker AJ; Cox CD; Coleman PJ
J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
Winrow CJ; Gotter AL; Cox CD; Tannenbaum PL; Garson SL; Doran SM; Breslin MJ; Schreier JD; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
Neuropharmacology; 2012 Feb; 62(2):978-87. PubMed ID: 22019562
[TBL] [Abstract][Full Text] [Related]
9. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia.
Neubauer DN
Curr Opin Investig Drugs; 2010 Jan; 11(1):101-10. PubMed ID: 20047164
[TBL] [Abstract][Full Text] [Related]
10. Orexin receptor antagonists: medicinal chemistry and therapeutic potential.
Roecker AJ; Coleman PJ
Curr Top Med Chem; 2008; 8(11):977-87. PubMed ID: 18673167
[TBL] [Abstract][Full Text] [Related]
11. Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal.
Sakurai T; Mieda M
Trends Pharmacol Sci; 2011 Aug; 32(8):451-62. PubMed ID: 21565412
[TBL] [Abstract][Full Text] [Related]
12. Physiology. The perfect hypnotic?
Mignot E
Science; 2013 Apr; 340(6128):36-8. PubMed ID: 23559238
[No Abstract] [Full Text] [Related]
13. Orexin receptors as therapeutic drug targets.
Gotter AL; Roecker AJ; Hargreaves R; Coleman PJ; Winrow CJ; Renger JJ
Prog Brain Res; 2012; 198():163-88. PubMed ID: 22813974
[TBL] [Abstract][Full Text] [Related]
14. Orexins and orexin receptors: from molecules to integrative physiology.
Matsuki T; Sakurai T
Results Probl Cell Differ; 2008; 46():27-55. PubMed ID: 18204827
[TBL] [Abstract][Full Text] [Related]
15. Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation.
Beuckmann CT; Yanagisawa M
J Mol Med (Berl); 2002 Jun; 80(6):329-42. PubMed ID: 12072908
[TBL] [Abstract][Full Text] [Related]
16. Aspects of the narcolepsy-cataplexy syndrome in O/E3-null mutant mice.
De La Herrán-Arita AK; Zomosa-Signoret VC; Millán-Aldaco DA; Palomero-Rivero M; Guerra-Crespo M; Drucker-Colín R; Vidaltamayo R
Neuroscience; 2011 Jun; 183():134-43. PubMed ID: 21435382
[TBL] [Abstract][Full Text] [Related]
17. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.
Di Fabio R; Pellacani A; Faedo S; Roth A; Piccoli L; Gerrard P; Porter RA; Johnson CN; Thewlis K; Donati D; Stasi L; Spada S; Stemp G; Nash D; Branch C; Kindon L; Massagrande M; Poffe A; Braggio S; Chiarparin E; Marchioro C; Ratti E; Corsi M
Bioorg Med Chem Lett; 2011 Sep; 21(18):5562-7. PubMed ID: 21831639
[TBL] [Abstract][Full Text] [Related]
18. Reverse pharmacology of orexin: from an orphan GPCR to integrative physiology.
Sakurai T
Regul Pept; 2005 Mar; 126(1-2):3-10. PubMed ID: 15620407
[TBL] [Abstract][Full Text] [Related]
19. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders.
Nishino S
Expert Opin Investig Drugs; 2007 Nov; 16(11):1785-97. PubMed ID: 17970638
[TBL] [Abstract][Full Text] [Related]
20. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status.
Mieda M; Sakurai T
CNS Drugs; 2013 Feb; 27(2):83-90. PubMed ID: 23359095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
